ADMA BIOLOGICS CLASS ACTION LAWSUIT: AN AUTHORITATIVE AND METICULOUS INVESTOR PLAYBOOK [2026]
Key Details of the ADMA Biologics Class Action Lawsuit (June, 2028)
The ADMA Biologics class action lawsuit seeks to represent purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”).
Key Details of the Lawsuit
- Class Period in the ADMA Biologics class action lawsuit: The ADMA Biologics class action lawsuit seeks to represent purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”).
- Lead Plaintiff Deadline: August 10, 2026.
- Core Allegations
- Channel Stuffing: ADMA allegedly induced its distributors to take excess product (such as their flagship drug ASCENIV) by offering rebates and extended payment terms, thereby artificially inflating revenue.
- Undisclosed Related-Party Transactions: The company failed to disclose a material distribution relationship with Genesis BioPharma Services, an entity that allegedly operated out of ADMA’s own corporate headquarters.
- Inadequate Internal Controls: The company failed to maintain accurate financial disclosures, leading to materially false and misleading statements to the market.
- Stock Price Decline: Following the release of the Culper Research report, ADMA Biologics stock plunged over 29% across two consecutive trading days (dropping from a close of $13.59 to $9.63 per share), significantly injuring investors.
Key Aspects of the ADMA Biologics on Class Action Lawsuit
The fraud: This involves a company or its executives intentionally making false or misleading statements to manipulate the stock market. This can include concealing important information that, if known, would have affected an investor’s decision to buy, sell, or hold the stock.
- The class period: This is thetimeframe during which the alleged fraud took place. It typically starts when the misleading information is released and ends when the truth is fully disclosed to the public, often leading to a significant drop in the stock price. The class period in the ADMA Biologics class action lawsuit is all purchasers or acquirers of Via Transportation, Inc. (NYSE: VIA) common stock pursuant and/or traceable to Via Transportation’s offering documents issued in connection with Via Transportation’s September 15, 2025 initial public offering (the “IPO”).
- Investor eligibility: To be included, you must have purchased or sold the company’s securities during the class period and suffered an economic loss.
- Lead plaintiff: A court-approved lead plaintiff represents the entire class, oversees the ADMA Biologics class action lawsuit and has the authority to approve settlements on behalf of all class members.
- Legal basis: These lawsuits are based on federal and state securities laws, such as the Securities Act of 1933 and the Securities Exchange Act of 1934.
- Benefits: Class actions give individual investors leverage against large companies and allow them to share the costs of litigation through a contingency-fee arrangement, meaning the lawyers are paid only if the class wins.
- Participation: Investors who are eligible to join the class do not have to join and can “opt out” to pursue their own individual lawsuit, though this requires hiring and paying a private attorney.
How it Works
- A lawsuit is initiated by one or more investors, called the “lead plaintiffs,” on behalf of a larger group of investors, or the “class”.
- The “class period” is defined as the specific timeframe during which the alleged fraudulent activity took place. Only those who bought or sold the security during this period are eligible to participate.
- A lead plaintiff is appointed to represent the class. Under the Private Securities Litigation Reform Act (PSLRA), the court will typically appoint the investor with the largest financial interest in the outcome of the case.
- The case is litigated, which may include a lengthy discovery phase for gathering evidence.
- The case can be settled or go to trial. Most class actions are resolved through settlements, which can include cash or stock paid into a common fund for the class. The lead plaintiff and class counsel approve any settlement before it is finalized.
Common Types of Misconduct
- Securities fraud class actions can arise from various types of misconduct by a company, its officers, or others involved in the sale of its securities, including:
- Making false or misleading statements in SEC filings, prospectuses, or earnings announcements.
- Overstating a company’s revenues or profits through fraudulent or “creative” accounting.
- Failing to disclose material information that would significantly alter an investor’s view.
- Engaging in market manipulation to artificially inflate or deflate a security’s price.
What Plaintiffs Must Prove
To succeed in a federal securities fraud class action, plaintiffs must prove several elements:
- Material misstatement or omission: The company made a false or misleading statement, or failed to disclose a material fact.
- Scienter: The defendant acted with an intent to deceive, manipulate, or defraud.
- Reliance: The plaintiff relied on the misstatement or omission when buying or selling the security. For publicly traded securities, this can be proven through the “fraud-on-the-market” theory, which presumes the market price reflects all public, material information.
- Economic loss: The plaintiff suffered a financial loss.
- Loss causation: The company’s misstatement or omission directly caused the plaintiff’s loss, often demonstrated by a stock price drop after the truth is revealed in a “corrective disclosure“
How to Get Involved
- If you bought a security during the alleged class period and suffered a loss, you are generally automatically included in the class. You don’t have to take any action unless you want to file a claim for recovery later.
- You may be notified of a class action by mail if you are an eligible class member.
- You may be able to become a lead plaintiff by applying within 60 days of the first lawsuit being announced.
- If you believe you may have a claim, you can contact a securities class action law firm for guidance.
What Is a Notice in a Class Action
- A notice in a class action refers to the formal communication sent to potential class members informing them about the lawsuit and their rights to participate in it.
- This notice is a crucial part of the class action process as it ensures that all individuals who may be affected by the outcome of the ADMA Biologics class action lawsuit are aware of their rights and can choose whether to opt-in or opt-out of the class.
- The notice typically contains information about the nature of the ADMA Biologics class action lawsuit, the claims being made, and the potential benefits or risks associated with participation. It also provides instructions on how to file a claim or request exclusion from the class.
- Overall, the notice serves to promote transparency and fairness in the class action process by ensuring that all affected individuals have an opportunity to exercise their legal rights.
Allegations in the ADMA Biologics Class Action Lawsuit
The ADMA Biologics class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that:
- ADMA Biologics engaged in an undisclosed related party transaction;
- ADMA Biologics used channel stuffing to create an appearance of revenue; and
- ADMA Biologics lacked adequate internal controls.
On March 24, 2026, Culper Research issued a report entitled “ADMA Biologics Inc (ADMA): Channel Stuffing, an Undisclosed Related Party Distributor, and -3% Real Growth in 2025 vs. +20% Reported.” Culper Research allegedly asserted that ADMA Biologics’ “reported growth is a fiction driven more than entirely be a de facto channel stuffing scheme and an undisclosed related party distributor,” adding that had ADMA Biologics “held payment terms steady rather than extending terms to inflate reported revenues, [ADMA Biologics] would have reported year-over-year revenue declines of 3% in 2025.”
On this news, the price of ADMA Biologics stock declined over 16%, according to the ADMA Biologics class action lawsuit.
On March 25, 2026, ADMA Biologics issued a press release entitled “ADMA Biologics Addresses Misleading Short-Seller Report,” allegedly stating that the Culper Research report was “premised on speculative assertions derived from unidentified and unreliable sources and contains numerous misleading, false and inaccurate statements.”
Then, on March 26, 2026, Investing.com published an article entitled “Cantor downgrades ADMA Biologics stock rating on short report concerns.”
The article allegedly reported that Cantor Fitzgerald downgraded ADMA Biologics to Neutral from Overweight and that investors “expressed disappointment” in ADMA Biologics’ response to the Culper Research report.
On this news, the price of ADMA Biologics stock fell more than 13%, according to the ADMA Biologics class action lawsuit.
Rights of Investors in the ADMA Biologics Class Action Lawsuit
Investors affected by the ADMA Biologics class action lawsuit possess specific rights that they can exercise. Understanding these rights is vital for anyone considering involvement in the Zoetis class action lawsuit.
Right to Information
- Investors have the right to receive accurate and timely updates regarding the ADMA Biologics class action lawsuit.
- This includes information on the case’s progress, potential settlements, and any necessary actions they may need to undertake.
Right to Participate
- Affected investors have the right to join the ADMA Biologics class action lawsuit.
- This allows them to collaborate with other investors in seeking compensation for their losses without the burden of filing individual lawsuits.
Right to Legal Representation
- Investors can seek legal counsel to navigate the complexities of the ADMA Biologics lawsuit.
- Legal professionals can provide guidance and support throughout the process.
- If you suffered substantial losses and wish to serve as lead plaintiff of the ADMA Biologics class action lawsuit or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected].
The Eligibility Criteria for Lead Plaintiff Appointment in the ADMA Biologics Class Action Lawsuit
To be eligible for appointment as the lead plaintiff in the ADMA Biologics Class Action Lawsuit, an investor must meet the following criteria:
- Securities Acquisition: The ADMA Biologics class action lawsuit seeks to represent purchasers or acquirers of ADMA Biologics, Inc. (NASDAQ: ADMA) publicly traded securities between August 9, 2024 and March 25, 2026, inclusive (the “Class Period”).
- Financial Losses: The investor must have suffered financial losses as a direct result of the alleged securities fraud perpetrated by ADMA Biologics and its executives.
- Typicality and Adequacy: The investor’s legal claims must be typical of those asserted on behalf of the class, and they must demonstrate their ability to adequately represent the interests of the entire class through experience, resources, and the absence of conflicts of interest.
It is crucial to note that both domestic and international investors who meet these criteria are eligible to seek appointment as the lead plaintiff in the class ADMA Biologics Class Action Lawsuit as courts have consistently recognized the rights of non-U.S. investors in securities class actions.
Contingency Fee Agreements: No Cost to Hire a Lawyer
- No Fee: It does not cost anything to hire a lawyer if you are eligible for an ADMA Biologics lawsuit. We take all cases on a contingency basis which means we do not get paid unless we win or settle your case.
- Talk with a Lawyer Free of Charge: A lawyer can explain the process of an ADMA Biologics lawsuit and answer any questions you may have free of charge.
Frequently Asked Questions About the ADMA Biologics Class Action Lawsuit
What initiated the ADMA Biologics class action lawsuit?
The ADMA Biologics class action lawsuit is initiated by investors alleging that ADMA Biologics provided misleading information regarding its financial health and operations, resulting in financial losses.
How can I join the ADMA Biologics class action lawsuit?
If you purchased shares during the class period and suffered a loss, then you are automatically a member of the ADMA Biologics lawsuit and do not need to do anything at this point unless you are considering moving for lead plaintiff.
What are the potential benefits of a ADMA Biologics class action lawsuit?
Class action lawsuits like the ADMA Biologics class action lawsuit allow individual investors to collectively seek justice and compensation, which might be challenging to pursue individually. They also promote corporate accountability.
How long will the ADMA Biologics class action lawsuit take to resolve?
The duration of class action lawsuits can vary significantly, depending on the complexity of the case, legal strategies, and whether settlements are reached. It could take several months to years to resolve the lawsuit.
What is the role of a lead plaintiff in the ADMA Biologics class action lawsuit?
A lead plaintiff is responsible for selecting and monitoring lead counsel responding to discovery requests, providing testimony when needed, reviewing key filings, and participating in settlement negotiations. They act as a fiduciary for the entire class, overseeing the litigation process to ensure the best possible outcome for all class members.
Contact Timothy L. Miles Today About a ADMA Biologics Class Action Lawsuit
The most important thing you need to know is you can call me at no charge if you wish to serve as lead plaintiff of the
ADMA Biologics
class action lawsuit, or just have general questions about you rights as a shareholder, please contact attorney Timothy L. Miles of the Law Offices of Timothy L. Miles, at no cost, by calling 855/846-6529 or via e-mail at [email protected]. (24/7/365).
Timothy L. Miles, Esq.
Law Offices of Timothy L. Miles
Tapestry at Brentwood Town Center
300 Centerview Dr. #247
Mailbox #1091
Brentwood,TN 37027
Phone: (855) Tim-MLaw (855-846-6529)
Email: [email protected]
Website: www.classactionlawyertn.com
Facebook Linkedin Pinterest youtube